Magnesium L-Threonate Supplement

## What it is Magnesium L-threonate (Mg-T) is the magnesium salt of L-threonic acid, a metabolite of vitamin C. It was developed at MIT by Liu and colleagues in the late 2000s and patented as Magtein by AIDP/Magceutics, with the explicit design goal of producing a magnesium form that crosses the blood-brain barrier more effectively than other commercial salts (oxide, citrate, glycinate, malate, taurate). The scientific origin is Liu 2010 (Neuron), which reported that supplementing aged rats with magnesium L-threonate elevated cerebrospinal fluid magnesium roughly 15%, increased hippocampal synaptic density, and improved performance on memory tasks. The same effect was not observed with equivalent oral doses of magnesium chloride or other salts. The paper anchored the MIT/Magtein commercial story and remains the most-cited evidence for the CNS-penetration claim. The US supplement market launched Magtein products around 2011. The compound is sold as a stand-alone supplement, in nootropic stacks, and as a magnesium replacement option marketed specifically for cognitive and sleep applications. Typical doses are 1500 to 2000 mg of Magtein per day (delivering roughly 144 mg of elemental magnesium), split into two or three doses. The positioning relative to other magnesium forms matters. Magnesium glycinate is the conventional choice for sleep, anxiety, and general magnesium repletion; it is well-absorbed and well-tolerated and has decades of clinical use. Magnesium oxide is poorly absorbed and used mostly as a laxative. Magnesium citrate is well-absorbed and inexpensive. Magnesium taurate is occasionally used for cardiovascular indications. Magnesium L-threonate is positioned as the cognitive form, distinct in mechanism rather than a higher-quality replacement for the others. Elemental magnesium content matters when comparing across forms. A 2000 mg dose of Magtein delivers ~144 mg of elemental magnesium. The same elemental dose from glycinate would be ~770 mg of magnesium glycinate. Mg-T is therefore not a high-yield magnesium-repletion strategy on a per-pill basis; its value proposition rests entirely on the CNS-penetration claim and downstream cognitive effects, not on systemic magnesium delivery. ## Mechanism of action Magnesium is a cofactor for over 300 enzymatic reactions and is essential for ATP synthesis, neuromuscular transmission, and NMDA receptor function. The blood-brain barrier (BBB) regulates CNS magnesium tightly: CSF magnesium is roughly 1.2-fold the unbound plasma fraction, and the entry kinetics are slow. Most oral magnesium salts raise plasma magnesium modestly without producing meaningful elevation of CSF or brain tissue magnesium. The Liu 2010 hypothesis is that magnesium L-threonate crosses the BBB more efficiently because the threonate moiety functions as an organic transport facilitator. The proposed mechanism involves uptake via threonate-related transporters and slower hepatic first-pass than other organic salts, allowing more intact compound to reach systemic circulation and CNS. Downstream of elevated brain magnesium, the proposed effects include enhanced NMDA receptor function (magnesium gates the NMDA channel), increased synaptic density via TrkB and BDNF signaling, and improved long-term potentiation (LTP), the molecular substrate of memory formation. The Liu 2010 paper reported all three signals in aged rats. The mechanistic case for human translation rests on the assumption that the rodent CSF-elevation finding generalizes to humans. Direct measurement of CSF magnesium in human Mg-T trials has not been routinely performed; the human evidence relies on cognitive surrogate endpoints, which are noisier than direct mechanism readouts. Pharmacokinetics: oral Mg-T is absorbed in the small intestine, with elemental magnesium peaking 1 to 3 hours post-dose. The threonate moiety is metabolized rapidly. Plasma magnesium changes after a single Mg-T dose are similar to other oral magnesium forms. The differential CNS uptake, if real, manifests over weeks of consistent dosing rather than acutely. ## Evidence base by outcome ### Synaptic density and CNS magnesium in rodents B-tier (single dominant study). Liu 2010 reported the elevated CSF magnesium and synaptic density signal in aged rats. The work has been extended by the same group in subsequent papers. Independent replication outside the Liu/Magceutics network is limited. ### Cognitive function in older adults with subjective decline C-tier. Wroolie 2013 (n=14 menopausal women, open-label) reported small cognitive improvements over 4 weeks. Liu 2016 (Magtein-funded, n=44 older adults with cognitive impairment, 12 weeks) reported improvements in memory and executive function on standardized tests versus placebo. Mickley 2024 (n=109, double-blind, Magceutics-funded) reported sleep-quality improvements with secondary cognitive signals. The pattern is consistent in direction but the funding monoculture and small sample sizes warrant caveats. ### Sleep quality C-tier. Mickley 2024 reported subjective sleep improvements at 2000 mg/day. Anecdotal user reports describe sleep benefits similar to or distinct from other magnesium forms. The evidence base is preliminary; whether the sleep benefit derives from CNS magnesium elevation specifically or from systemic magnesium repletion is not clear. ### Anxiety D-tier. Limited human trial data on anxiety endpoints. Mechanistic plausibility (NMDA modulation, GABA-related effects) is reasonable but not directly tested. ### Migraine and headache D-tier. Magnesium broadly has moderate evidence for migraine prophylaxis at high doses, but the trials have used magnesium oxide or citrate rather than Mg-T. No specific Mg-T migraine trials. ### Mood and depression D-tier. Magnesium broadly has some evidence in depression. No Mg-T-specific trials for mood endpoints. ### Long-term cognitive outcomes D-tier. No trial extends beyond 12 to 24 weeks. Long-term effects on cognitive trajectory or dementia risk are not characterized. ### Safety and tolerability B-tier. Trials report favorable safety with mild GI upset in a small minority. The compound has been on the consumer market since 2011 without emergent safety concerns. ## Dosage and administration The canonical Magtein dose is 1500 to 2000 mg of Mg-T per day, delivering roughly 108 to 144 mg of elemental magnesium. The trial doses have been at the upper end (2000 mg/day). Dosing is typically split: morning and evening, or morning and pre-bedtime for users targeting sleep. Some protocols use an evening-only dose for sleep applications. For users using Mg-T as their primary magnesium source, the elemental dose (108 to 144 mg) is below the recommended daily intake for adults (310 to 420 mg). Pairing Mg-T with another magnesium form (glycinate or citrate) for systemic repletion while preserving the cognitive positioning is common in stack-conscious user practice. Take with or without food per tolerability. The product can produce loose stools in sensitive users; splitting the dose reduces this. No cycling is part of the protocol. Continuous daily dosing is the standard. ## Side effects and safety GI effects (loose stools, mild diarrhea) are the most common adverse events, occurring in roughly 5 to 10% of users at 2000 mg/day. Splitting the dose or reducing to 1500 mg often resolves this. Headache and mild fatigue have been reported in a small minority; both are non-specific and may reflect placebo or unrelated causes. Magnesium toxicity (hypermagnesemia) is theoretically possible at very high doses, but the elemental magnesium content of typical Mg-T dosing is well below the level that produces hypermagnesemia in users with intact renal function. Renal impairment is a contraindication for high-dose magnesium of any form. Users with chronic kidney disease (eGFR below 30) should avoid magnesium supplements without medical supervision. Drug interactions are limited. Magnesium can chelate certain antibiotics (tetracyclines, fluoroquinolones) and bisphosphonates, reducing their absorption; separate dosing by 2 to 4 hours. Magnesium can potentiate the effect of muscle relaxants and certain blood-pressure medications at high doses. Pregnancy and lactation: standard magnesium safety applies. Routine use of Mg-T specifically has not been studied in these populations. ## Stack interactions and timing Mg-T pairs reasonably with other cognitive supplements: omega-3, B vitamins, creatine. The combinatorial evidence is essentially absent in trials. Magnesium glycinate is the natural pairing for users who want systemic magnesium repletion plus the Mg-T cognitive positioning. Take Mg-T in the morning for cognitive support and glycinate in the evening for sleep, or distribute both across the day. The two should not be considered redundant; they serve different physiological targets in the magnesium replacement framing. L-theanine, ashwagandha, and Mg-T are commonly stacked for evening cognitive and sleep support. Mechanistic complementarity is plausible. Dosing timing: morning and evening split is typical for cognitive applications. Evening-only dosing for sleep applications is common. Some users find morning dosing produces alertness and evening dosing produces sleep, which is an inconsistency that has not been resolved in the trial literature. ## Practical notes Magtein is the original branded ingredient and most consumer products specify Magtein content rather than generic Mg-T. Generic magnesium L-threonate from non-Magtein sources has appeared in lower-cost products; the bioequivalence to Magtein has not been formally demonstrated. Quality varies across products. Look for products specifying Magtein on the label, or third-party-tested generic Mg-T from reputable manufacturers. Mg-T is more expensive than other magnesium forms (typically 30 to 60 USD per month at clinical doses, versus 10 to 20 USD for glycinate at equivalent elemental delivery). The elemental magnesium content matters for users tracking total magnesium intake. Mg-T is a low-yield form per gram of compound; pairing with other forms is reasonable for users with documented magnesium insufficiency. Expect any cognitive effect to develop over weeks. The Liu 2010 rodent timeline was 4 to 8 weeks; human trials have used 4 to 24 weeks. Acute single-dose cognitive effects have not been demonstrated. The honest framing for the use case: the Liu 2010 rodent mechanism is interesting, the cognitive trials are mostly small and Magtein-funded, and the practical case for Mg-T over other magnesium forms rests on the unproven assumption that the differential CNS-penetration claim generalizes to humans. For users prioritizing systemic magnesium repletion, glycinate is cheaper, well-tolerated, and well-evidenced. For users specifically targeting cognitive endpoints with Mg-T, the choice is reasonable but the evidence base is preliminary, and pairing Mg-T with another magnesium form for total elemental delivery is sensible.